Disease on EC 3.5.1.88 - peptide deformylase
Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Anemia, Hypochromic
Inhibition of peptide deformylase in Nicotiana tabacum leads to decreased D1 protein accumulation, ultimately resulting in a reduction of photosystem II complexes
Anemia, Hypochromic
Inhibition of peptide deformylase in Nicotiana tabacum leads to decreased D1 protein accumulation, ultimately resulting in a reduction of photosystem II complexes.
Burkitt Lymphoma
Inhibition of human mitochondrial peptide deformylase causes apoptosis in c-myc-overexpressing hematopoietic cancers.
Infections
A Repurposing Approach for Uncovering the Anti-Tubercular Activity of FDA-Approved Drugs with Potential Multi-Targeting Profiles.
Infections
Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
Infections
Comparative Analysis of the Antibacterial Activity of a Novel Peptide Deformylase Inhibitor, GSK1322322.
Infections
Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance.
Infections
Determination of disk diffusion and MIC quality control ranges for GSK1322322, a novel peptide deformylase inhibitor.
Infections
Discovery of piperazic acid peptide deformylase inhibitors with in vivo activity for respiratory tract and skin infections.
Infections
Disk diffusion quality control guidelines for NVP-PDF 713: a novel peptide deformylase inhibitor.
Infections
In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
Infections
Inhibition of chlamydial infection in the genital tract of female mice by topical application of a peptide deformylase inhibitor.
Infections
Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.
Infections
Pharmacokinetics and tolerability of IDP-73152 mesylate after a single oral administration under fasted and fed conditions in healthy volunteers.
Infections
Pharmacokinetics/Pharmacodynamics of Peptide Deformylase Inhibitor GSK1322322 against Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus in Rodent Models of Infection.
Infections
Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates.
Infections
Quantification of IDP-73152, a novel antibiotic, in plasma from mice, rats and humans using an ultra-high performance liquid chromatography/tandem mass spectrometry method for use in pharmacokinetic studies.
Leukemia, Myeloid, Acute
Inhibition of human mitochondrial peptide deformylase causes apoptosis in c-myc-overexpressing hematopoietic cancers.
Neoplasms
High-throughput identification of inhibitors of human mitochondrial peptide deformylase.
Neoplasms
Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics.
Neoplasms
Inhibition of human mitochondrial peptide deformylase causes apoptosis in c-myc-overexpressing hematopoietic cancers.
Neoplasms
Peptide deformylase inhibitor actinonin reduces celastrol's HSP70 induction while synergizing proliferation inhibition in tumor cells.
Neoplasms
Structure and activity of human mitochondrial peptide deformylase, a novel cancer target.
Neoplasms
Structure-Based Drug Design of Small Molecule Peptide Deformylase Inhibitors to Treat Cancer.
Neoplasms
Synthesis and Anticancer Activity of Novel Actinonin Derivatives as HsPDF Inhibitors.
Pneumonia
Comparative Analysis of the Antibacterial Activity of a Novel Peptide Deformylase Inhibitor, GSK1322322.
Pneumonia
Determination of disk diffusion and MIC quality control ranges for GSK1322322, a novel peptide deformylase inhibitor.
Pneumonia
Efficacy of BB-83698, a novel peptide deformylase inhibitor, in a mouse model of pneumococcal pneumonia.
Pneumonia
Evaluation of LBM415 (NVP PDF-713), a novel peptide deformylase inhibitor, for treatment of experimental Mycoplasma pneumoniae pneumonia.
Pneumonia
Pharmacokinetics/Pharmacodynamics of Peptide Deformylase Inhibitor GSK1322322 against Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus in Rodent Models of Infection.
Pneumonia, Bacterial
In vitro and intracellular activities of peptide deformylase inhibitor GSK1322322 against Legionella pneumophila isolates.
Pneumonia, Pneumococcal
Efficacy of BB-83698, a novel peptide deformylase inhibitor, in a mouse model of pneumococcal pneumonia.
Respiratory Tract Diseases
Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance.
Respiratory Tract Infections
Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
Respiratory Tract Infections
Disk diffusion quality control guidelines for NVP-PDF 713: a novel peptide deformylase inhibitor.
Respiratory Tract Infections
Pharmacokinetics and tolerability of IDP-73152 mesylate after a single oral administration under fasted and fed conditions in healthy volunteers.
Soft Tissue Infections
Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
Tuberculosis
A Repurposing Approach for Uncovering the Anti-Tubercular Activity of FDA-Approved Drugs with Potential Multi-Targeting Profiles.
Tuberculosis
BB-3497, a peptide deformylase inhibitor, is active against Mycobacterium tuberculosis.
Tuberculosis
Carfilzomib as a potential inhibitor of NADH-dependent enoyl-acyl carrier protein reductases of Klebsiella pneumoniae and Mycobacterium tuberculosis as a drug target enzyme: insights from molecular docking and molecular dynamics.
Tuberculosis
Glycine in the conserved motif III modulates the thermostability and oxidative stress resistance of peptide deformylase in Mycobacterium tuberculosis.
Tuberculosis
Identification of regions involved in enzymatic stability of peptide deformylase of Mycobacterium tuberculosis.
Tuberculosis
In vitro and ex vivo activity of peptide deformylase inhibitors against Mycobacterium tuberculosis H37Rv.
Tuberculosis
Novel peptidomimetic peptide deformylase (PDF) inhibitors of Mycobacterium tuberculosis.
Tuberculosis
Peptide deformylase inhibitors of Mycobacterium tuberculosis: synthesis, structural investigations, and biological results.
Tuberculosis
Peptide deformylase--a promising therapeutic target for tuberculosis and antibacterial drug discovery.
Tuberculosis
The carboxy-terminal end of the peptide deformylase from Mycobacterium tuberculosis is indispensable for its enzymatic activity.
Tuberculosis
Therapeutic potential of peptide deformylase inhibitors against experimental tuberculosis.
Tuberculosis
Three consecutive arginines are important for the mycobacterial peptide deformylase enzyme activity.
html completed